VRTX
Vertex Pharmaceuticals Inc / Ma
$528.04
+30.03 (+6.03%)
At close · Jul 2
Market Cap
$134.02B
Shares
253,805,417
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Nancy Thornberry | member of the Company's Board of Directors | Appointed | 2026-05-13 |
| Jennifer Schneider | member of the Company's Board of Directors | Appointed | 2026-05-13 |
| Bruce Sachs | member of the Company's Board of Directors | Appointed | 2026-05-13 |
| Diana McKenzie | member of the Company's Board of Directors | Appointed | 2026-05-13 |
| Jeffrey Leiden | member of the Company's Board of Directors | Appointed | 2026-05-13 |
| Michel Lagarde | member of the Company's Board of Directors | Appointed | 2026-05-13 |
| Reshma Kewalramani | member of the Company's Board of Directors | Appointed | 2026-05-13 |
| Alan Garber | member of the Company's Board of Directors | Appointed | 2026-05-13 |
| Lloyd Carney | member of the Company's Board of Directors | Appointed | 2026-05-13 |
| Sangeeta Bhatia | member of the Company's Board of Directors | Appointed | 2026-05-13 |
Key facts
CIK
875320
CUSIP
92532F100
13F (30d)
60 filings
18 filers
Visit website
Investor relations